These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32756167)

  • 41. Copeptin, B-type natriuretic peptide and cystatin C are associated with incident symptomatic PAD.
    Fatemi S; Acosta S; Gottsäter A; Melander O; Engström G; Dakhel A; Zarrouk M
    Biomarkers; 2019 Sep; 24(6):615-621. PubMed ID: 31215249
    [No Abstract]   [Full Text] [Related]  

  • 42. N-terminal-pro-B-type-natriuretic peptide associated with 2-year mortality from both cardiovascular and non-cardiovascular origins in prevalent chronic hemodialysis patients.
    Kawagoe C; Sato Y; Toida T; Nakagawa H; Yamashita Y; Fukuda A; Iwatsubo S; Fujimoto S
    Ren Fail; 2018 Nov; 40(1):127-134. PubMed ID: 29457529
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction.
    Costello-Boerrigter LC; Boerrigter G; Redfield MM; Rodeheffer RJ; Urban LH; Mahoney DW; Jacobsen SJ; Heublein DM; Burnett JC
    J Am Coll Cardiol; 2006 Jan; 47(2):345-53. PubMed ID: 16412859
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients.
    Racek J; Králová H; Trefil L; Rajdl D; Eiselt J
    Nephron Clin Pract; 2006; 103(4):c162-72. PubMed ID: 16645318
    [TBL] [Abstract][Full Text] [Related]  

  • 45. NT-proBNP and Echocardiographic Parameters for Prediction of Cardiovascular Outcomes in Patients with CKD Stages G2-G4.
    Untersteller K; Girerd N; Duarte K; Rogacev KS; Seiler-Mussler S; Fliser D; Rossignol P; Heine GH
    Clin J Am Soc Nephrol; 2016 Nov; 11(11):1978-1988. PubMed ID: 27515593
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Amount of left ventricular hypertrophy determines the plasma N-terminal pro-brain natriuretic peptide level in patients with hypertrophic cardiomyopathy and normal left ventricular ejection fraction.
    Kim SW; Park SW; Lim SH; Kwon SU; Choi YJ; Park MK; Lee SC; Lee SH; Park JE; Jeon ES
    Clin Cardiol; 2006 Apr; 29(4):155-60. PubMed ID: 16649724
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
    Koç M; Bozkurt A; Yildiray-Sahin D; Unal I; Acartürk E
    Cardiol J; 2009; 16(1):43-9. PubMed ID: 19130415
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of Cardiac and Non-Cardiac Biomarkers for Risk Stratification in Elderly Patients with Non-Massive Pulmonary Embolism.
    Vuilleumier N; Simona A; Méan M; Limacher A; Lescuyer P; Gerstel E; Bounameaux H; Aujesky D; Righini M
    PLoS One; 2016; 11(5):e0155973. PubMed ID: 27219621
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized trial of bioelectrical impedance analysis versus clinical criteria for guiding ultrafiltration in hemodialysis patients: effects on blood pressure, hydration status, and arterial stiffness.
    Onofriescu M; Mardare NG; Segall L; Voroneanu L; Cuşai C; Hogaş S; Ardeleanu S; Nistor I; Prisadă OV; Sascău R; Covic A
    Int Urol Nephrol; 2012 Apr; 44(2):583-91. PubMed ID: 21688195
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pro B-type Natriuretic Peptide and Midregional Proadrenomedullin are Associated with Incident Carotid Stenosis During Long Term Follow-up.
    Fatemi S; Acosta S; Zarrouk M; Engström G; Melander O; Gottsäter A
    J Stroke Cerebrovasc Dis; 2021 Jan; 30(1):105403. PubMed ID: 33160126
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correlation to NT-ProBNP and remodeling after cardiac surgery.
    Boer BP; Vieira ML; Sampaio RO; Abensur H; Oliveira AG; Fernandes JR; Grinberg M
    Arq Bras Cardiol; 2013 May; 100(5):469-75. PubMed ID: 23579620
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Population-based detection of systolic and diastolic dysfunction with amino-terminal pro-B-type natriuretic peptide.
    Abhayaratna WP; Marwick TH; Becker NG; Jeffery IM; McGill DA; Smith WT
    Am Heart J; 2006 Nov; 152(5):941-8. PubMed ID: 17070165
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of a dialysis session on the prognostic values of NT-proBNP, troponins, endothelial damage and inflammation biomarkers.
    Codognotto M; Piccoli A; Zaninotto M; Mion MM; Ruzza L; Barchita A; Naso A; Plebani M
    J Nephrol; 2010; 23(4):465-71. PubMed ID: 20540041
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association between changes in N-terminal pro-brain natriuretic peptide levels and changes in left ventricular mass index in stable hemodialysis patients.
    Choi SY; Lee JE; Jang EH; Kim MO; Baek H; Ki CS; Park SW; Kim DJ; Huh WS; Oh HY; Kim YG
    Nephron Clin Pract; 2008; 110(2):c93-100. PubMed ID: 18815449
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of midregional pro-A-type natriuretic peptide and the N-terminal pro-B-type natriuretic peptide for predicting mortality and cardiovascular events.
    van Hateren KJ; Alkhalaf A; Kleefstra N; Groenier KH; de Jong PE; de Zeeuw D; Gans RO; Struck J; Bilo HJ; Gansevoort RT; Bakker SJ
    Clin Chem; 2012 Jan; 58(1):293-7. PubMed ID: 21948291
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NT-pro-BNP as marker for cardiac strain that may be caused by high-output arteriovenous shunting in a haemodialysis patient. A case report.
    Wärja M; Laveborn E; Ott M; Jonsson AP; Stegmayr B
    BMC Nephrol; 2020 Dec; 21(1):544. PubMed ID: 33349246
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
    Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
    JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potential determinants of the E/e' ratio in non-dialysis compared with dialysis patients.
    Hsu HC; Norton GR; Robinson C; Woodiwiss AJ; Dessein PH
    Nephrology (Carlton); 2021 Dec; 26(12):988-998. PubMed ID: 34272789
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adropin and irisin: New biomarkers of cardiac status in patients with end-stage renal disease? A preliminary study.
    Kałużna M; Pawlaczyk K; Schwermer K; Hoppe K; Człapka-Matyasik M; Ibrahim AY; Sawicka-Gutaj N; Minczykowski A; Ziemnicka K; Oko A; Ruchała M
    Adv Clin Exp Med; 2019 Mar; 28(3):347-353. PubMed ID: 30525316
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Soluble neprilysin, NT-proBNP, and growth differentiation factor-15 as biomarkers for heart failure in dialysis patients (SONGBIRD).
    Claus R; Berliner D; Bavendiek U; Vodovar N; Lichtinghagen R; David S; Patecki M; Launay JM; Bauersachs J; Haller H; Hiss M; Balzer MS
    Clin Res Cardiol; 2020 Aug; 109(8):1035-1047. PubMed ID: 32002632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.